scholarly journals Evaluation of Effect of Lymph Node Involvement on Prognosis of Clear Cell Renal Cell Cancer and Role of Tumor Size and Grade on Prediction of Lymph Node Involvement

2014 ◽  
Vol 13 (4) ◽  
pp. 192-195
Author(s):  
Nurullah Hamidi ◽  
Mehmet İlker Gökçe ◽  
Evren Süer ◽  
Sümer Baltacı ◽  
Yaşar Bedük
Keyword(s):  
Lymph Node ◽  
Renal Cell Cancer ◽  
Tumor Size ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Lymph Node Involvement ◽  
Node Involvement

Role of lymph node dissection in renal cell cancer

2019 ◽  
Vol 37 (3) ◽  
pp. 187-192 ◽  
Author(s):  
Nirmal Thampi John ◽  
Kyle A. Blum ◽  
A. Ari Hakimi
Keyword(s):  
Lymph Node ◽  
Lymph Node Dissection ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Node Dissection

scholarly journals Evaluation of Role of Inflammatory Markers for the Prediction of Recurrence on Pathologic T1a Clear Cell Renal Cell Cancer Patients

2016 ◽  
Vol 15 (1) ◽  
pp. 18-21
Author(s):  
Mehmet İlker Gökçe ◽  
Nurullah Hamidi ◽  
Barış Esen ◽  
Semih Tangal ◽  
Evren Süer ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Inflammatory Markers ◽  
Clear Cell ◽  
Cell Cancer

C07 Polymorphisms of RAGE and glyoxalase I genes in patients with clear cell renal cell cancer

2013 ◽  
Vol 12 (4) ◽  
pp. e1115, C07
Author(s):  
M. Chocholatý ◽  
K. Havlová ◽  
M. Schmidt ◽  
M. Kalousová ◽  
M. Jáchymová ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Glyoxalase I

scholarly journals Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

2006 ◽  
Vol 17 (8) ◽  
pp. 1185-1196 ◽  
Author(s):  
P. Schöffski ◽  
H. Dumez ◽  
P. Clement ◽  
A. Hoeben ◽  
H. Prenen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 275-275
Author(s):  
Grant D. Stewart ◽  
Sarah J. Welsh ◽  
Stephan Ursprung ◽  
Ferdia Gallagher ◽  
Iosif Mendichovszky ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Surgical Approach ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Response Rate ◽  
Clear Cell ◽  
Cell Cancer ◽  
Surgical Morbidity ◽  
Venous Tumor Thrombus ◽  
Extent Of Surgery

275 Background: Venous tumor thrombus (VTT) extension occurs in 4-15% cases of renal cell cancer (RCC). The Mayo classification distinguishes 4 levels of VTT extension between the renal vein and supradiaphragmatic inferior vena cava (IVC). Although surgery is performed with curative intent, mortality is high (5-15%) with complications increasing with the level of the VTT. 5-year survival rates are poor; ~40-65% in non-metastatic RCC. It is hypothesised that neoadjuvant targeted therapy could downstage the VTT reducing the extent of surgery, leading to reduced surgical morbidity and mortality, and increased survival. However, level I or II evidence is lacking. NAXIVA provides the first level II evidence in this patient group, assessing the response of VTT to axitinib. Extensive translational sampling will provide in depth interrogation of VTT (using genomics, proteomics, immunophenotyping and metabolomics) to examine the role of the tumor microenvironment of VTT and response to axitinib. Methods: NAXIVA was a single arm, single agent, multi-center phase 2 feasibility study of axitinib in patients with both metastatic and non-metastatic clear cell RCC prior to nephrectomy and thrombectomy. A Simon two stage minimax design was adopted and the trial designed for adequate power to distinguish a <5% from a >25% improvement in the Mayo VTT level. 21 patients were recruited over a 24 month period between 15/Dec/2017 and 06/Jan/2020 at 5 sites across the UK. Patients were treated with 8 weeks of axitinib (starting dose 5mg bd, increasing to 10mg bd as tolerated) prior to planned surgery. The primary endpoint was the percentage of evaluable patients with an improvement in VTT according to the Mayo classification (assessed using MRI abdomen scans at screening and week 9, prior to surgery. Secondary endpoints were percentage change in surgical approach, percentage change in VTT height, response rate (by RECIST) and evaluation of surgical morbidity assessed by Clavien-Dindo classification. Results: The percentage of evaluable patients with an improvement in VTT according to the Mayo classification was 26.58% [80% CI: 15.76%, 39.74%] (6 of 21 evaluable patients). 35.29% (6 of 17 patients who progressed to surgery) had a change in surgical approach to a less invasive option. There was a median percentage reduction in VTT height of 21.49% (SD=27.60%). The response rate (by RECIST) in the evaluable population was 61.90% SD, 14.29% PR, 9.52% PD. In terms of surgical morbidity 11.76% (2 of 17 patients who progressed to surgery) experienced a Clavien-Dindo 3 or greater complication (0 CD3, 1 CD4, 1 CD5). Conclusions: NAXIVA provides unique prospective data on the feasibility of neoadjuvant axitinib administration to down stage IVC VTT and reduce the extent of surgery. Work is ongoing to establish predictors of response. Clinical trial information: NCT03494816 .

The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy

2014 ◽  
Vol 10 (14) ◽  
pp. 2177-2187 ◽  
Author(s):  
Katarzyna Kaminska ◽  
Cezary Szczylik ◽  
Fei Lian ◽  
Anna M Czarnecka
Keyword(s):  
Prostaglandin E2 ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cancer Development

International renal-cell-cancer study. VI. The role of medical and family history

1996 ◽  
Vol 66 (6) ◽  
pp. 723-726 ◽  
Author(s):  
Brigitte Schlehofer ◽  
Wolfgang Pommer ◽  
Anders Mellemgaard ◽  
John H. Stewart ◽  
Margaret McCredie ◽  
...  
Keyword(s):  
Family History ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cancer Study

scholarly journals A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients

2016 ◽  
Vol 23 (8) ◽  
pp. 2006-2018 ◽  
Author(s):  
Iris J.H. van Vlodrop ◽  
Sophie C. Joosten ◽  
Tim De Meyer ◽  
Kim M. Smits ◽  
Leander Van Neste ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Promoter Methylation ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Gene Promoter ◽  
Marker Panel ◽  
Methylation Marker
Sign in / Sign up

Export Citation Format

Share Document